

## Special Issue

# T-cell Immunity and Viral Pathogenicity on Vaccine Efficacy

### Message from the Guest Editors

We welcome research articles, reviews, and perspectives that examine, study and contribute conceptually in the development of COVID and effective AIDS vaccines. In the effort to be spearheaded by the editorial office, we will transform the contributions into deep knowledge of vaccinology, and apply Applied Science to further the vaccine development. Contributions in the following are welcome:

- Studies on the relationship of cytokine storm with the spike protein and/or SARS-CoV-2 replication in lung, kidney or other target organs/tissues
- Studies of T-cell, B-cell immune response against the spike proteins of SARS-CoV-2 before and/or after COVID vaccine immunization
- Studies of Kick-Kill (Shock-Kill) and Block-Lock on HIV cure, and/or the strategies on vaccines for HIV cure
- Model, technology on study of HIV-1 or SARS-CoV-2 pathogenicity

**The submission date is 9/6/2022 and deadline is**

**4/6/2023.** Once you are registered, click here to go to the submission form:

<https://susy.mdpi.com/user/manuscripts/upload/00dec7c11d6f1424ac7392a86e5a7e9f?journal=vaccines> We look forward to hearing from you!

---

### Guest Editors

Prof. Dr. Clyde S. Crumpacker

Harvard Medical School, Beth Israel Deaconess Medical Center,  
Boston, MA 02215, USA

Prof. Dr. Philip W. Askenase

Allergy & Clinical Immunology, Yale School of Medicine, New Haven, CT  
06510, USA

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/134387](https://mdpi.com/si/134387)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).